Company news
Alphamab Oncology news in 2025
Alphamab Oncology's news releases, calls and decks from 2025, newest first.
Alphamab Oncology Announces IND Application for a Phase II Clinical Study of HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 as First-line Treatment of Advanced Cervical Cancer was Officially Accepted by CDE
December 29, 2025
Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Breakthrough Therapy Designation by the FDA for the Treatment of PROC
December 19, 2025
Alphamab Oncology Announces IND Application for Innovative PD-L1/ VEGFR2 Bispecific ADC JSKN027 was Officially Accepted by CDE
December 17, 2025
Stay True to Our Original Aspiration, Forge Ahead into the Future｜Alphamab Oncology 2025 R&D Day Successfully Held
December 10, 2025
Alphamab Oncology Showcases Cutting-edge Breakthroughs and Innovative Achievements at the 16th World ADC San Diego
November 5, 2025
Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Fast Track Designation by FDA for the Treatment of PROC
October 27, 2025
Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for Colorectal Cancer
October 26, 2025
Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/αvβ6 Bispecfic ADC JSKN022
October 24, 2025
Biparatopic HER2-targeting ADC JSKN003 Was Granted Another Breakthrough Therapy Designation for HER2-Positive Advanced Colorectal Cancer
October 20, 2025
Alphamab Oncology Presented Multiple Clinical Data on Biparatopic HER2-targeting ADC JSKN003 at ESMO Congress 2025
October 20, 2025
Research Updates on a Phase III Clinical Trial of Anbenitamab (KN026) Presented at ESMO Congress 2025 LBA Oral Presentation Session
October 18, 2025
The New Drug Application for KN026 (Anbenitamab Injection) Has Been Accepted by the National Medical Products Administration
September 11, 2025
Alphamab Oncology Reports 2025 Interim Results and Business Highlights
August 28, 2025
Alphamab Oncology Announces IND Application for Innovative PD-L1/αvβ6 Bispecific ADC JSKN022 was Officially Accepted by CDE
August 3, 2025
Alphamab Oncology Announces Anti-HER2 Biparatopic ADC JSKN003 Received U.S. FDA IND Approval to Initiate a Phase II Clinical Study for Platinum-Resistant Ovarian Cancer
July 31, 2025
Alphamab Oncology Announces Anti-HER2 Biparatopic ADC JSKN003 Obtained Orphan Drug Designation from the U.S. FDA for the Treatment of GC/GEJ
July 28, 2025
Alphamab Oncology Presented Multiple Clinical Data of Anti-HER2 Biparatopic ADC JSKN003 at the 2025 ASCO Annual Meeting
June 2, 2025
A Pivotal Phase II/III Clinical Study of Anti-HER2 Bispecific Antibody KN026 Have Met the Primary Endpoint of PFS at Interim Analysis
April 30, 2025
Alphamab Oncology Presented Preclinical Data on Two Novel Bispecific ADCs at the 2025 AACR Annual Meeting
April 29, 2025
Alphamab Oncology Reports Full Year 2024 Financial Results and Business Highlights
March 25, 2025
Anti-HER2 Biparatopic ADC JSKN003 Has Been Granted Breakthrough-Therapy Designation for the Treatment of PROC
March 17, 2025
First Patient Dosed in a Phase III Clinical Study of Anti-HER2 Biparatopic ADC JSKN003 for the Treatment of HER2-positive Breast Cancer
February 27, 2025